Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.

With programs focusing on counseling and prevention, Egis was present on the Day of Vascular Diseases.

According to our mission, we serve people with all of our skills, so that they can live a long and healthy life. That is why we chose to support the comprehensive nationwide screening program as a Golden Sponsor in 2019. The state-of-the-art screening truck will tour around the country until Christmas, stopping by 200 spots to offer screenings in 37 different areas.

One of the pillars of our corporate culture is innovation. We do not only talk about it, but enjusre the flow of ideas with annual forums that offer space for making proposals in connection with scientific research, manufacturing, how to make our administrative process more effective and the latest item on our agenda: digitalization.

Egis Russia’s Buy for Good campaign that was carried out in 2018 won the award of ‘Best Social Projects in Russia’ in the category of medical and social projects.

Egis Pharmaceutical PLC’s Senior pharmaceutical sales rep participated very successfully at Medigames. Having won two gold medals, four silvers, and three bronze, pharmacist Dr. Judit Karagics contributed considerably to the 3rd place Hungary reached in the medal table. This excellent performance strengthens Egis’ reputation in the international target groups.